JAAHM
Journal of Advanced Analytics in Healthcare Management

Advancing Treatment and Management of Congestive Heart Failure through Integration of Digital Twin Technology and Big Data Analytics

Samina Ahmed
Kohat University of Science and Technology, Karak Campus
Imran Khan
Gomal University, Dera Ismail Khan Campus

Submitted: 13 June 2023
Accepted: 15 December 2023
Published: 07 January 2024

Abstract

Congestive heart failure (CHF) is a chronic, progressive condition in which the heart is unable to pump sufficient blood to meet the body's needs. The prevalence and healthcare costs associated with CHF are expected to rise as the population ages. Advances in digital health technologies present new opportunities to improve CHF treatment and management. This paper proposes integrating digital twin technology and big data analytics to create personalized virtual heart models that can enable precision medicine, predictive analytics, and virtual clinical trials. A digital twin is a virtual representation of a physical asset that uses real-world data to simulate its near real-time status. For CHF, the digital twin can incorporate the patient's clinical data, imaging, genomics, and wearables data to create a dynamic model of their heart function. Big data analytics of population health data can identify clinical best practices to inform the digital twin models. The virtual heart models can then be used to optimize medications, predict decompensation, and test new therapies in silico. This novel approach can ultimately empower patients and providers with data-driven, individually tailored solutions for managing CHF. Critical research is needed to develop robust virtual physiology models and validate their use for therapeutic decision-making. If successful, the integration of digital twins and big data could significantly advance CHF care and outcomes.

Keywords: *congestive heart failure, digital twin, virtual physiology, big data, predictive analytics, precision medicine*

Introduction

Congestive heart failure (CHF) is a chronic, progressive condition characterized by the heart's inability to pump sufficient blood to meet the body's metabolic demands. It affects over 6 million adults in the United States and over 26 million worldwide. The prevalence of CHF continues to grow due to the aging population and improving survival rates from cardiovascular conditions like hypertension, coronary artery disease, and myocardial infarction, which often precede the onset of CHF [1]. The trajectory of CHF includes periods of acute decompensation leading to hospitalization, impaired quality of life, and ultimately a 5-year mortality rate approaching 50%. Beyond its clinical burden, CHF also bears a heavy economic toll, with healthcare costs projected to increase from $30 billion currently to over $70 billion by 2030 in the US alone. There is a critical need for innovative solutions to improve the prevention, diagnosis, and management of CHF [2].

Recent advances in digital health technologies, including wearable biosensors, big data analytics, and computer modeling, offer new opportunities to transform CHF care. The convergence of these technologies can enable a transition from the traditional one-size-fits-all approach to precision and personalized medicine [3]. This paper specifically proposes integrating digital twin technology and big data analytics to create virtual heart models for individualized CHF assessment and treatment [4]. A digital twin is a physics-based virtual representation of a physical asset or system that uses real-world data to mirror its near real-time status. Digital twins are emerging in industries like aerospace, manufacturing, and energy to optimize performance and predict failures. In healthcare, digital twins can similarly allow in silico experimentation to inform therapeutic decision-making. When combined with big data analytics, digital twins have the potential to integrate multiscale patient data into personalized virtual models of physiology for precision medicine applications [5].

This paper first provides background on the pathophysiology, diagnosis, treatment, and monitoring of CHF. Next, it introduces digital twin technology and its applications in healthcare [6]. The potential benefits of digital twin virtual heart models for advancing CHF care are then discussed, highlighting areas such as precision medicine, predictive analytics, and virtual clinical trials. Critical research needs to develop robust virtual physiology models and clinically validate their use are also examined. The paper concludes by discussing the challenges and future outlook for this novel approach of integrating digital twins and big data analytics to transform CHF assessment and care.

Background

Pathophysiology of Congestive Heart Failure

CHF occurs when the heart is unable to supply sufficient blood flow to meet the body's metabolic demands. It can result from disorders that impair the heart's pumping capability (systolic dysfunction) or its ability to relax and fill with blood (diastolic dysfunction), with both often coexisting. The most common cause of CHF is coronary artery disease, where atherosclerotic blockages prevent adequate oxygenation of the myocardium, resulting in ischemia, infarction, and remodeling that reduce cardiac output. Other etiologies include hypertension, valvular disease, arrhythmias like atrial fibrillation, and cardiomyopathies from genetic mutations, toxins, or infection [7].

Figure 1. An illustration of the digital twin concept [8]



Regardless of initial cause, CHF triggers common compensatory mechanisms that become maladaptive over time. Reduced cardiac output activates the sympathetic nervous system and renin-angiotensin-aldosterone system to increase heart rate, contractility, and blood volume. The overloaded ventricles remodel by dilating, thinning, and changing shape. Neurohormonal and inflammatory cytokines are also upregulated [9]. Initially these mechanisms help maintain perfusion, but ultimately they become deleterious, causing additional myocardial damage. The progressive structural and functional deterioration of the heart leads to a downward spiral of decreasing cardiac output and worsening CHF [10], [11].

Diagnosis and Prognostication

CHF arises from diverse etiologies and its clinical presentation is heterogeneous, making early diagnosis challenging. Symptoms like dyspnea, fatigue, and fluid retention are nonspecific. Clinical exam may detect signs such as elevated jugular venous pressure, pulmonary crackles, and peripheral edema, but findings can be subtle. Echocardiography is the mainstay for assessing cardiac structure and function. Other modalities like cardiac magnetic resonance imaging can provide additional details on morphology, fibrosis, perfusion, and mechanical defects to elucidate the phenotype and etiology [12]. B-type natriuretic peptide levels and cardiopulmonary exercise testing also aid diagnosis and prognostication.

Once CHF is established, its severity is classified by the New York Heart Association system based on functional limitation. However, static classification fails to capture the dynamic, progressive nature of CHF. Risk prediction models like the Seattle Heart Failure Model integrate clinical and laboratory variables to assess prognosis, survival, and hospitalization risk. Still, uncertainty remains high, emphasizing the need for better predictors of adverse events. Integrating emerging biomarkers, genomics, and sensor data could improve prognostication. Ongoing phenotyping and risk stratification are critical to guide CHF therapy and monitoring [13].

Treatment Approaches

While no cure exists for CHF, pharmacotherapy can alleviate symptoms and slow progression. Medications target neurohormonal activation (ACE inhibitors, beta blockers, aldosterone antagonists) and fluid retention (diuretics). In select cases, device therapies like biventricular pacemakers and implantable cardioverter-defibrillators may help. For end-stage CHF, ventricular assist devices or transplantation could be considered. While these interventions can improve outcomes, their effects are often inadequate and temporary. CHF management remains primarily reactionary - deterioration typically prompts escalation of therapies or hospitalization until the patient stabilizes. However, the underlying progressive cycle continues. There is an unmet need for approaches that can predict decompensation before it occurs and enable preventive care. Personalized, data-driven solutions could help break this cycle and bend the trajectory of CHF.

Monitoring and Health Information Technology

Close monitoring is essential for guiding CHF management. Frequent physician office visits with physical exam, vital signs, labs, and imaging provide periodic snapshots. However, ambulatory, continuous monitoring is needed to detect dynamic changes. Emerging health information technologies can facilitate this. Wearable sensors track biometrics, with multisensor algorithms identifying aberrant patterns predictive of decompensation. Smartphone apps allow patients to log symptoms and share data. Electronic health records centralize data from encounters adoring [14]. Telehealth and mobile health platforms enable remote care. While promising, these disparate systems lack integration and sufficient analytics. There remains an unmet need for comprehensive platforms that can assimilate multiscale data into actionable, personalized care models. Digital twin technology, when combined with analytics of big health datasets, could provide such a solution.

Digital Twin Technology

A digital twin is a virtual representation of a physical asset or system throughout its lifecycle, synchronized by integrating data from sensors, models, and simulations. This creates a living digital profile that mirrors the status of its real-world counterpart to enable analysis, prediction, and optimization. Digital twins are gaining use in industrial sectors like aviation, power grids, manufacturing, oil and gas for applications such as predictive maintenance, virtual testing, and process improvement. In healthcare, digital twins could similarly allow in silico modeling of patients for personalized care. A virtual physiological model that integrates all available data can enable simulation of disease pathways and treatment responses specific to an individual.

Digital twins can be descriptive, predictive, or prescriptive depending on model complexity . Descriptive twins integrate historical data to recreate a static representation of an asset. Predictive twins forecast future performance through computational modeling and machine learning. Prescriptive twins use optimization algorithms to recommend actions that will achieve desired outcomes. For robust healthcare applications, prescriptive twins that can advise on therapeutic decisions are needed. This requires accurate predictive models based on comprehensive, timely data [15].

Creating predictive digital twins first involves data acquisition from all relevant sources - sensors, imaging, labs, exams, health records, and more. The real-world data is used to develop and continuously update a virtual model that emulates the physical asset's performance characteristics. Physics-based models represent system dynamics using mathematical equations. Data-driven models use techniques like machine learning to derive empirical associations from big datasets. Hybrid models combining both approaches provide the most flexibility and accuracy. With sufficient data quality and quantity, digital twins can model complex physiology and disease processes for in silico experimentation and decision support.

Table 1. Traditional Heart Failure Monitoring Approaches

Monitoring Approach	Description	Limitations
Physical exam	Heart, lung, abdominal, and extremity exam during office visits to detect signs of congestion and impaired perfusion	Limited by infrequency and availability of office visits, inter-rater variability
Vital signs	Measurement of pulse, respiratory rate, blood pressure, weight	Spot checks lacking continuity; manual entry into records
Laboratory tests	Blood tests of renal function, electrolytes, natriuretic peptides	Infrequent; limited insight into interim changes
Echocardiography	Ultrasound imaging to evaluate cardiac structure and function	Episodic snapshots lacking continuity; inter-rater variability in interpretation

Applications in Healthcare

While still an emerging concept in healthcare, groups have prototyped digital twin applications for various uses:

Biopharma: Drug modeling and virtual clinical trials to evaluate safety and efficacy prior to human testing.

Medical devices: Virtual models for design optimization and performance testing.

Diagnostics: Decision support systems that integrate patient data for differential diagnosis.

Personalized medicine: Virtual models of disease tailored to the individual for precision monitoring and treatment

Each use aims to leverage multiscale data and simulations to enable in silico analysis and care. However, most healthcare digital twin applications remain in conceptual or pilot stages. Robust virtual physiology models are needed before clinical implementation. CHF management is a promising use case for healthcare digital twins, where the need and potential impact is high.

Digital Heart Twins for Advancing CHF Management

Digital twin technology has the potential to revolutionize the management of chronic heart failure (CHF) by creating personalized virtual heart models that integrate a multitude of patient-specific factors. These models can encompass not only genetic predispositions but also consider comorbidities, medication history, and other relevant clinical data [16]. By incorporating imaging data such as echocardiography and continuous biometrics from wearable sensors, these virtual representations offer a high-fidelity snapshot of the patient's cardiovascular status. This comprehensive digital profile enables healthcare professionals to gain a deeper understanding of the intricate dynamics underlying CHF progression and response to treatment.

The integration of diverse data sources within these virtual heart models facilitates a multifaceted approach to optimizing CHF care. By analyzing genetic markers and patient-specific risk factors, clinicians can tailor treatment strategies to address individual vulnerabilities and optimize therapeutic outcomes. Furthermore, the incorporation of real-time biometric data allows for continuous monitoring of disease progression and treatment response, enabling timely interventions to prevent exacerbations and improve patient outcomes. Additionally, these virtual heart models serve as invaluable tools for research and development, providing a platform for the exploration of novel therapeutic targets and the evaluation of emerging interventions through virtual clinical trials [17]. Moreover, the utilization of digital twin technology in CHF management extends beyond the realm of clinical practice to encompass patient education and empowerment. By visualizing complex cardiac physiology in an accessible format, patients gain insights into their condition and treatment options, fostering a sense of engagement and autonomy in their healthcare journey. Furthermore, virtual heart models facilitate shared decision-making between patients and providers, enabling collaborative care plans that align with patient preferences and goals. Ultimately, the integration of personalized virtual heart models into CHF care holds immense promise in improving patient outcomes, enhancing clinical decision-making, and advancing our understanding of cardiovascular disease pathophysiology.

Precision Medicine and Patient Empowerment

The virtual heart twin provides an integrated, longitudinal overview of an individual's unique CHF profile that is constantly updated as new data is collected. This can aid precision medicine by elucidating nuances in how CHF manifests and progresses in each patient [18]. Understanding the specific phenotype and biomolecular pathways involved allows therapies to be tailored based on projected response, rather than the standard trial-and-error approach. The digital twin can forecast outcomes of medication regimen changes to determine optimal, patient-specific selection and dosing. Simulating first-line use of sacubitril-valsartan over an ACE inhibitor for a patient with heart failure with reduced ejection fraction is one example.

The digital twin can also serve as an educational tool during office visits or remotely to empower patients to visualize and understand their condition. Many patients have trouble conceptualizing abstract changes described during a cardiology consult. Allowing them to see and interact with a dynamic digital model of their heart can improve their engagement and adherence. Patients can also view projected outcomes adjusted to different medication or lifestyle changes, guiding shared decision making.

Table 2. Classes of Heart Failure Medications and Their Mechanisms

Medication Class	Mechanism
ACE inhibitors	Block conversion of angiotensin I to angiotensin II to reduce vasoconstriction and sodium retention
Angiotensin receptor blockers	Inhibit binding of angiotensin II to receptors, producing effects similar to ACE inhibitors
Beta blockers	Block beta receptors to reduce sympathetic activation of the heart
Aldosterone antagonists	Inhibit effects of aldosterone to reduce fluid retention and fibrosis
Diuretics	Increase excretion of fluid through the kidneys to reduce congestion

Predictive Analytics and Deterioration Detection

A major potential of digital twins is prognostic capability. Continuously integrating streams of diverse data allows earlier detection of states indicative of impending decompensation. Machine learning algorithms can identify subtle patterns predictive of deterioration missed during sporadic in-person assessments. If validated, these algorithms can enable weeks or months of lead time to allow preventive intervention, forestalling acute events and hospitalization [19]. This predictive analytics approach is far superior to reacting once overt symptoms appear. Data types with prognostic value include biometrics (heart rate variability, blood pressure, activity patterns), labs (natriuretic peptides), and imaging (echocardiographic strain). Digital twins can integrate and analyze these biomarkers in ways unattainable during in-person visits.

Predictive functionality can also inform dynamic risk stratification to guide monitoring and care decisions. For low-risk periods, remote monitoring may suffice. Higher risk may prompt increased vigilance or therapy escalation. Patient trajectories can be compared against "digital cohorts" with similar CHF phenotypes to benchmark deviation from expected baselines, improving accuracy. If validated for clinical use, such predictive analytics could significantly improve outcomes [20], [21].

Virtual Clinical Trials and In Silico Experimentation

Pharmaceutical therapies for CHF have plateaued over the past decades, with few novel medications. Those that do emerge often fail in late-stage trials due to unanticipated side effects or complications. Digital heart twins derived from virtual patient cohorts can enable extensive in silico experimentation to accelerate therapeutic development. Virtual trials using the digital twin models can optimize dosing, identify at-risk groups, and predict side effects prior to any human testing, improving safety. New combinatorial therapies can also be tested by simulation [22]. For approved therapies, comparing the virtual cohort treatment responses against real-world outcomes can reveal new mechanisms and areas for improvement. Digital twins could make clinical trials faster, more economical, and effective.

Beyond drug development, digital twins also allow in silico testing of device therapies like ventricular assist devices (VADs). Determining proper VAD placement and settings traditionally requires repeated imaging and trial-and-error adjustment. Virtual implantation and hemodynamic modeling using the digital twin could help optimize these devices and procedures. Overall, digital twins can enable extensive therapeutic experimentation and innovation tailored to the individual that is impossible solely through physical trials.

Research Needs and Priorities

While promising, substantial research is imperative before clinical adoption of digital CHF twin models. Computational models of cardiac anatomy and physiology have reached high fidelity , but accurately replicating complex pathophysiology is challenging. Congestion, neurohormonal signaling, and impaired energetics must be modeled. Integrating multiomics data (genomics, proteomics, metabolomics) could help capture nuanced biochemical status. Standardizing data inputs and outputs is critical for integrating models across platforms and applying learnings across populations. Robust predictive analytics are also crucial for clinical implementation. Streaming multivariate sensor data and healthcare records into predictive algorithms requires data engineering workflows. Time series analysis, probabilistic modeling, and deep learning methods should be tested. Key will be moving from just correlating patterns post hoc to accurately forecasting outcomes prospectively. All models require extensive validation across diverse cohorts to avoid bias and misleading outputs.

Clinical integration is equally important. Usability assessments across patients and providers can optimize design. Standards for data privacy and cybersecurity must be established. Cost-effectiveness needs evaluation. Randomized controlled trials are essential to validate model utility for improving diagnostic, prognostic, and therapeutic accuracy over standard of care. Global partnerships, open-source platforms, and health equity considerations can help disseminate and implement digital twins in varied care settings and patient populations. Substantial interdisciplinary research across medicine, engineering, ethics, health systems, and data science is indispensable to actualize digital CHF twins. If successful, the models could provide clinicians with real-time, individualized guidance for precision care, while giving patients greater insight into their condition. The potential to bend the clinical and economic burden of CHF is immense.

Outlook and Conclusions

Chronic heart failure (CHF) poses a significant burden on millions of individuals worldwide, characterized by a poor prognosis despite the array of available therapeutic interventions. However, with the advent of advancements in sensor technologies, computing capabilities, and data science, there arises a promising opportunity to revolutionize the evaluation and management of CHF through the integration of digital twin technology and big data analytics [23], [24]. By harnessing these tools, it becomes feasible to develop personalized virtual heart models that offer insights into each patient's unique CHF profile. These models can serve as powerful assets in the realm of precision medicine, predictive analytics, and virtual clinical trials, thereby potentially improving patient outcomes and treatment efficacy [25].

Despite the promise of digital twin technology in CHF management, significant foundational research remains imperative. The development of accurate cardiac physiologic models, predictive algorithms, and robust validation protocols is essential to ensure the reliability and efficacy of these virtual representations of the heart. Moreover, the translation of such technology into clinical practice faces various technical, regulatory, and clinical barriers. Addressing these challenges necessitates interdisciplinary collaboration to navigate complex regulatory frameworks, ensure data privacy and security, and establish standards for clinical validation [26].

Interdisciplinary research efforts must extend beyond technical aspects to encompass broader considerations of ethics, equity, and patient-provider dynamics. As digital twin technology becomes integrated into healthcare systems, it is crucial to ensure that these models are interpretable, trustable, and equitable across diverse patient populations. Furthermore, efforts should be directed towards enhancing patient-provider relationships through the meaningful integration of digital tools into clinical practice. By fostering a holistic approach to the development and implementation of digital twin technology in CHF management, healthcare systems can strive towards improving patient care and outcomes in a sustainable and equitable manner [27]. If thoughtfully implemented, the future integration of virtual twins and big data could provide more holistic, proactive, preventive cardiology. Patients with CHF stand to benefit immensely from this novel paradigm of evidence-based, data-driven, individualized care. Digital transformation presents an unprecedented opportunity to bend the trajectory of CHF and improve clinical outcomes, functioning, and quality of life [28].

References

[1] A. Amin, S. Minaee, M. Chitsazan, N. Naderi, S. Taghavi, and M. Ardeshiri, “Can vitamin D supplementation improve the severity of congestive heart failure?,” *Congest. Heart Fail.*, vol. 19, no. 4, pp. E22–E28, Jul. 2013.

[2] V. Nagarajan, C. A. Cauthen, R. C. Starling, and W. H. W. Tang, “Prognosis of morbid obesity patients with advanced

heart failure," *Congest. Heart Fail.*, vol. 19, no. 4, pp. 160–164, Jul. 2013.
[3] C. Simbaqueba *et al.*, "Prognostic implications of relative hypochromia in ambulatory patients with chronic systolic heart failure," *Congest. Heart Fail.*, vol. 19, no. 4, pp. 180–185, Jul. 2013.
[4] M. Muniswamaiah, T. Agerwala, and C. C. Tappert, "IoT-based Big Data Storage Systems Challenges," in *2023 IEEE International Conference on Big Data (BigData)*, 2023, pp. 6233–6235.
[5] P. Green, B. A. Babu, S. Teruya, S. Helmke, M. Prince, and M. S. Maurer, "Impact of epoetin alfa on left ventricular structure, function, and pressure volume relations as assessed by cardiac magnetic resonance: the heart failure preserved ejection fraction (HFPEF) anemia trial," *Congest. Heart Fail.*, vol. 19, no. 4, pp. 172–179, Jul. 2013.
[6] H.-H. Tung, C.-Y. Lin, K.-Y. Chen, C.-J. Chang, Y.-P. Lin, and C.-H. Chou, "Self-management intervention to improve self-care and quality of life in heart failure patients," *Congest. Heart Fail.*, vol. 19, no. 4, pp. E9–E16, Jul. 2013.
[7] J. J. Smith and H. J. Levine, "Systolic dysfunction of the ventricle in congestive heart failure: pathophysiology, diagnosis, and therapy," *Congest. Heart Fail.*, vol. 5, no. 1, pp. 10–26, Jan. 1999.
[8] G. M. Thiong'o and J. T. Rutka, "Digital twin technology: The future of predicting neurological complications of pediatric cancers and their treatment," *Front. Oncol.*, vol. 11, p. 781499, 2021.
[9] V. L. Serebruany *et al.*, "Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry for the Assessment of Platelet Function in Patients with Congestive Heart Failure," *Pathophysiol. Haemost. Thromb.*, vol. 32, no. 1, pp. 8–15, Jan. 2002.
[10] H. Suzuki, M. Naito, A. Matsumoto, K. Arakawa, M. Murakami, and T. Saruta, "Significance of vasopressin in congestive heart failure," *Pathophysiology*, vol. 1, p. 358, Nov. 1994.
[11] M. Muniswamaiah, T. Agerwala, and C. C. Tappert, "Big Data and Data Visualization Challenges," in *2023 IEEE*

International Conference on Big Data (BigData), 2023, pp. 6227–6229.
[12] M. Hamada *et al.*, "Comparison of angiotensin converting enzyme inhibitor with digoxin versus without digoxin for the treatment of congestive heart failure," *Pathophysiology*, vol. 1, p. 53, Nov. 1994.
[13] J. P. Navas and M. Martinez-Maldonado, "Pathophysiology of edema in congestive heart failure," *Heart Dis. Stroke*, vol. 2, no. 4, pp. 325–329, Jul. 1993.
[14] G. E. Batuwael, F. Sialana, and J. Tuharea, "Persepsi masyarakat Wahaeolon terhadap Peran dan Kedudukan Perempuan Modern di Kecamatan Leksula Kabupaten Buru Selatan," *Journal of Education Technology Information Social Sciences and Health*, vol. 1, no. 1, pp. 100–107, Jan. 2023.
[15] S. Syed, Z. Islam, and M. A. Qureshi, "Impact of untreated high blood pressure on renal function tests at initial diagnosis of hypertension," *INT. J. OF ENDORSING HEALTH SCI. RES. (IJEHSR)*, vol. 2, no. 2, p. 72, Dec. 2014.
[16] H. A. Schmidt, "Studies on the applicability of inulin labeled with i-131 in kidney function tests. I. Blood concentration level, renal accumulation and excretion of inulin in the rat and dog," *Klin. Wochenschr.*, vol. 42, pp. 966–967, Oct. 1964.
[17] F. Reubi, "Renal functional examinations. Chemical testing of the blood, semi-quantitative function tests and clearance technics," *J. Urol. Nephrol. (Paris)*, vol. 67, pp. 336–359, Jun. 1961.
[18] S. Dandage *et al.*, "Patient empowerment through summarization of discussion threads on treatments in a patient self-help forum," in *Precision Medicine Powered by pHealth and Connected Health*, Singapore: Springer Singapore, 2018, pp. 229–233.
[19] K. Pabreja and A. Bhasin, "A predictive analytics framework for blood donor classification," *Int. J. Big Data Anal. Healthc.*, vol. 6, no. 2, pp. 1–14, Jul. 2021.
[20] M. Seyedan and F. Mafakheri, "Predictive big data analytics for supply chain demand forecasting: methods, applications, and research opportunities," *J. Big Data*, vol. 7, no. 1, Dec. 2020.
[21] T. W. Wlodarczyk and T. J. Hacker, "Current trends in predictive analytics of big data," *Int. J. Big Data Intell.*, vol. 1, no. 3, p. 172, 2014.

[22] C. L. A. Wender, B. M. Sandroff, and D. Krch, "Rationale and methodology for examining the acute effects of aerobic exercise combined with varying degrees of virtual reality immersion on cognition in persons with TBI," *Contemp. Clin. Trials Commun.*, vol. 29, no. 100963, p. 100963, Oct. 2022.

[23] D. A. Pascual-Figal *et al.*, "Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study," *Eur. J. Heart Fail.*, vol. 25, no. 8, pp. 1352–1360, Aug. 2023.

[24] M. Muniswamaiah, T. Agerwala, and C. C. Tappert, "Context-aware query performance optimization for big data analytics in healthcare," in *2019 IEEE High Performance Extreme Computing Conference (HPEC-2019)*, 2019, pp. 1–7.

[25] A. Bosch *et al.*, "Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure," *ESC Heart Fail.*, vol. 10, no. 3, pp. 1635–1642, Jun. 2023.

[26] M. Metra *et al.*, "Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology," *Eur. J. Heart Fail.*, vol. 25, no. 6, pp. 776–791, Jun. 2023.

[27] Y. Watanabe *et al.*, "Utility of fractional excretion of urea nitrogen in heart failure patients with chronic kidney disease," *ESC Heart Fail.*, vol. 10, no. 3, pp. 1706–1716, Jun. 2023.

[28] J. H. Butt *et al.*, "Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER," *Eur. J. Heart Fail.*, Aug. 2023.